Qure.ai yesterday announced a collaboration with Microsoft in which Qure.ai’s lung cancer detection, measurement, and management solutions will be added to Microsoft’s Precision Imaging Network. This brings Qure.ai solutions to more U.S. hospitals and health systems. Qure.ai is already in more than 5000 sites, and expects to be in about 1000 more over the next year.
What’s unique about Qure.ai is that it can greatly expand the utility of chest X-rays. “You usually get a CT for diagnosis,” Jim Mercadante, chief commercial officer at Qure.ai told Inside Precision Medicine. “But with our suite of tools you can make more diagnoses more quickly.”
Peter Durlach, corporate VP and chief strategy officer, Microsoft Health and Life Sciences, said, “The integration of Qure.ai’s AI solutions into the Precision Imaging Network will help health systems unlock new levels of efficiency—from faster detection and diagnosis to more coordinated multidisciplinary care.”
Qure.ai’s lung cancer algorithms are built from Large Language Models (LLMs). Its solutions, Qure.ai says, improve clinical workflows among radiologists, pulmonologists, interventionalists, and thoracic surgery teams, thus speeding early detection, diagnosis, and treatment. Qure.ai aims to answer what they describe as the biggest cancer challenge in the U.S. today—diagnosing lung cancer quicker and more efficiently.
Lung cancer causes more deaths in the U.S. than colon, breast and prostate cancers combined. It is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women.
Mercadante said, “The Qure.ai and Microsoft collaboration brings new levels of choice and simplicity for hospitals and health systems across the U.S.A. It will power-up access to early detection, triage, and tracking to improve patient care, boost survival rates and reduce overall healthcare costs. It will also bolster a growing global roster of strategic alliances between Qure.ai, academia, governments, pharmaceutical, life science and tech companies, united in advancing the digitization of health.”
He added, “Recently, via a long-term partnership with AstraZeneca and the EDISON Alliance, Qure.ai achieved a unique five million scan milestone across 20 countries, applying AI to routine chest X-rays to illustrate the role AI can play in earlier lung cancer risk identification.”
That project proved the potential of the technology because they picked up many cancerous nodules that would have otherwise been overlooked. So many lung cancer scans are performed that better accuracy could greatly improve outcomes.
Durlach said, “This collaboration reflects Microsoft’s commitment to empowering healthcare organizations with secure, scalable cloud AI solutions that enable earlier interventions, improved patient outcomes, and drive sustainable transformation across the continuum of care.”
Qure.ai is deployed in over 105 countries across 5000+ sites. In 2025 it was recognized as a TIME100 Most Influential Company 2025 for the use of AI to reshape access and diagnosis of high-burden diseases worldwide. It has 19 FDA cleared findings for the identification, triage and management of Lung Cancer and Neurocritical findings.
The Qure.ai FDA-cleared lung cancer solutions can be deployed as individual products, or collectively as a suite for a unified and cohesive workflow. When deployed together, operational, clinical and economic advantages cascade downstream. From incidental detection of lung nodules on chest X-ray (qXR-LN), measurement and quantification on CT (qCT-LN Quant) through to patient management coordination (qTrack). The Qure.ai neurocritical solution (qER) triages emergency findings to support faster interventions and care.
